21 September 2020 in Head and Neck Pathology
5 June 2021 in Journal of Oral Pathology & Medicine
4 October 2024 in Head and Neck Pathology
Purpose: The current study aimed to investigate the use of surrogate immunohistochemical (IHC) markers of proliferation and stem cells to distinguish ameloblastoma (AB) from ameloblastic carcinoma (AC). Methods: The study assessed a total of 29 ACs, 6 ABs that transformed into ACs, and a control cohort of 20 ABs. The demographics and clinicopathologic details of the included cases of AC were recorded. The Ki-67 proliferation index was scored through automated methods with the QuPath open-source software platform. For SOX2, OCT4 and Glypican-3 IHC, each case was scored using a proportion of positivity score combined with an intensity score to produce a total score. Results: All cases of AC showed a relatively high median proliferation index of 41.7%, with statistically significant higher scores compared to ABs. ABs that transformed into ACs had similar median proliferation scores to the control cohort of ABs. Most cases of AC showed some degree of SOX2 expression, with 58.6% showing high expression. OCT4 expression was not seen in any case of AC. GPC-3 expression in ACs was limited, with high expression in 17.2% of ACs. Primary ACs showed higher median proliferation scores and degrees of SOX2 and GPC-3 expression than secondary cases. Regarding SOX2, OCT4 and GPC-3 IHC expression, no statistically significant differences existed between the cohort of ABs and ACs. Conclusion: Ki-67 IHC as a proliferation marker, particularly when assessed via automated methods, was helpful in distinguishing AC from AB cases. In contrast to other studies, surrogate IHC markers of embryonic stem cells, SOX2, OCT4 and GPC-3, were unreliable in distinguishing the two entities.
30 January 2025 in Journal of Oral Pathology & Medicine
Background: The study aimed to assess the radiologic‐specific growth rate of ameloblastomas, evaluating potential associations with demographics, radiologic features, histopathologic variants and proliferation indices. The results of this study will hopefully establish if any clinical or histopathologic features can elude fast‐growing ameloblastomas.Methods: Patients presenting with multiple radiographs before surgical intervention due to various healthcare constraints or patient factors were included in the study. The measurements from each radiograph included the lesion's length, height, width and amount of expansion in these dimensions. Furthermore, the circumference of the lesion was measured in sagittal, coronal and axial planes. The radiologic‐specific growth rate was assessed by calculating the difference in measurements from the initial to follow‐up radiographs divided by the duration between the visits to calculate the growth rate per year.Results: The specific growth rate was analysed between age groups, histopathologic variants and Ki‐67 values, with no statistically significant correlations found in all dimensions measured. A statistically significant faster growth (p = 0.04) was seen in females when measuring the mesial‐distal length. When comparing radiologic features, ameloblastomas with loss of border demarcation, severe cortical destruction and tooth displacement demonstrated statistically significant faster growth.Conclusion: This study found significant correlations with the growth rate of ameloblastomas, specifically in coronal dimensions, supporting the notion of buccal‐lingual growth/expansion for which ameloblastomas are known.
30 January 2025 in Head and Neck Pathology
Purpose: This study aimed to investigate the role of DNA ploidy and proliferation index in distinguishing ameloblastoma (AB) from ameloblastic carcinoma (AC). Methods: The study included 29 ACs, 6 conventional ABs that transformed into ACs, and a control cohort of 20 conventional ABs. The demographics and clinicopathologic details of the included cases were summarised and compared. The Ki-67 proliferation index was scored using the QuPath open-source software platform. DNA ploidy analysis was performed using high-resolution flow cytometry. Results: The cohort of ABs presented at an overall younger age compared to both primary and secondary ACs. There was a statistically significant difference between the median duration of the tumour when comparing primary and secondary ACs, with ACs presenting with longer durations than the AB cohort. All cases of AC showed a relatively high median proliferation index of 41.7%, with statistically significant higher scores compared to ABs. DNA ploidy analysis showed that all cases in the AB cohort were diploid. Two diploid cases of AB that transformed into ACs were aneuploid when the corresponding secondary AC was analysed. Fourteen cases of AC were diploid and 12 were aneuploid, with no statistically significant association found between DNA ploidy status of primary and secondary ACs. A statistically significant difference was noted when the DNA ploidy status of ABs was compared to that of ACs. When comparing the Ki-67 proliferation score of ACs to their DNA ploidy status, no statistically significant association was noted. Conclusion: DNA ploidy analysis and proliferation index via Ki-67 IHC are useful ancillary tests that may be used to support a diagnosis of AC and may assist in distinguishing between challenging cases of AB and AC.